

Bibliografia

1. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoprotein-an integrated approach to mechanisms and disorders. *N Engl J Med.* 1967; 276: 34-43, 94-103, 148-156, 215-225, 273-281.
2. Beaumont JL, Carlson LA, Cooper GR, et al. Classification of hyperlipidaemias and hyperlipoproteinemias. *Bull WHO.* 1970; 43: 891-915.
3. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study *Lancet.* 1977; 7: 965-658.
4. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. *Science.* 1986; 232: 34-47.
5. Goldstein JL, Brown MS. Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. *J Lipid Res.* 1984; 15: 1450-1461.
6. Sheperd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group (WOSCOPS). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med.* 1995; 16: 333: 1301-1307.
7. Scandinavian Simvastatin Survival Study Group (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the 4S. *Lancet.* 1994; 344: 1983-1989.
8. Sacks FM, Pfeffer MA, Moye La, et al. Cholesterol and Recurrent Events (CARE). The effect of pravastatin on coronary events after MI in patients with average cholesterol levels. *N Engl J Med.* 1996; 335: 1001-1009.
9. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med.* 1998; 339: 1349-1357.
10. Cholesterol Treatment Trialists (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. *Lancet.* 2005; 366: 1267-1278.
11. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA.* 2001; 285: 2486-2497.
12. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Circulation.* 2004; 110: 227-239.
13. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J.* 2011; 32: 1769-1818.
14. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. *Can J Cardiol.* 2009; 25: 567-579.
15. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *EurHeart J.* 2011; 32: 1345-1361.
16. Battaggia A, Giustini E, SIMG, Comitato Nazionale Clinical Governance. Progetto ASCO. Linee guida sulla gestione della dislipidemia in medicina generale. 2010; <http://www.progettoasco.it>
17. AIFA. Nota 13. Determinazione 6 giugno 2011 (GU 15 luglio 2011, n. 163).
18. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density li-

- poprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* 1972; 18: 499-502.
19. Brunzell JD. Hypertriglyceridemia. *N Engl J Med.* 2007; 357: 1009-1017.
 20. Arca M, Vega GL, Grundy SM. Hypercholesterolemia in post-menopausal women. Metabolic defects and response to low-dose lovastatin. *JAMA.* 1994; 271: 453-459.
 21. Barnett JB, Woods MN, Lamou-Fava S, et al. Plasma lipid and lipoprotein levels during the follicular and luteal phases of the menstrual cycle. *J Clin Endocrinol Metab.* 2004; 89: 776-782.
 22. Allison MA, Manson JE, Langer RD, et al. Women's Health Initiative and Women's Health Initiative Coronary Artery Calcium Study Investigators. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. *Menopause.* 2008; 15: 639-647.
 23. Greenland P, Alpert JS, Beller GA, et al. 2010ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2010; 56: e50-103.
 24. De Bacquer D, De Backer G. Electrocardiographic findings and global coronary risk assessment. *Eur Heart J.* 2002; 23: 268-270.
 25. U.S. Preventive Services Task Force. Screening for coronary heart disease: recommendation statement. *Ann Intern Med.* 2004; 140: 569-572.
 26. Gibbons LW, Mitchell TL, Wei M, et al. Maximal exercise test as a predictor of risk for mortality from coronary heart disease in asymptomatic men. *Am J Cardiol.* 2000; 86: 53-58.
 27. Greenland P, Graziano JM. Clinical practice. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing. *N Engl J Med* 2003; 349: 465-473.
 28. Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death in women: The St. James Women Take Heart Project. *Circulation.* 2003; 108: 1554-1559.
 29. Lorenz MW, Markus HS, Bots ML, et al. Prediction of Clinical Cardiovascular Events with Carotid Intima-Media Thickness. A systematic Review and Meta-Analysis. *Circulation.* 2007; 115: 459-467.
 30. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. *J Am Soc Echocardiography.* 2008; 21: 93-111.
 31. Ankle Brachial index Collaboration. Ankle Brachial Index combined with Framingham risk Score to predict cardiovascular events and mortality. A Meta-Analysis. *JAMA.* 2008; 300: 197-208.
 32. AMD-SID. Standard italiani per la cura del diabete mellito tipo 2. Linee guida e raccomandazioni. 2011; Formazione & Informazione Medica, Torino.
 33. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World heart federation; International atherosclerosis society; and International association for the study of obesity. *Circulation.* 2009; 120: 1640-1645
 34. Deshmukh M, Lee HW, McFarlane SI, Whalley-Connell A. Antihypertensive medications and their effects on lipid metabolism. *Curr Diab Rep.* 2008; 8: 214-220.
 35. Jukema JW, van der Hoorn JW. Amlodipine and atorvastatin in the atherosclerosis: a review of the potential of the combination therapy. *Expert Opin Pharmacother.* 2004; 5: 459-468.
 36. American Heart Association Nutrition Committee; Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006; a scientific statement from the American Heart Association Nutrition Committee. *Circulation.* 2006; 114: 82-96.
 37. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. *N Engl J Med.* 2002; 347: 1483-1492.

38. Bulbulia R, Bowman L, Wallendszus K, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. *Lancet*. 2011; 378: 2013-2020.
39. Sever PS, Chang CL, Gupta AK, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. *Eur Heart J*. 2011; 32: 2525-2532.
40. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008; 359: 2195-2207.
41. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*. 2011; 25; 377: 2181-2192.
42. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. *N Engl J Med*. 2011; 365: 2078-2087.
43. Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural history and treatment of familial hypercholesterolemia. *Atherosclerosis* 2003; 168: 1-14.
44. Gerdtts E, Rossebø AB, Pedersen TR, et al. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study). *Am J Cardiol*. 2010; 106: 1634-1639.
45. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*. 2010; 362: 1563-1574.
46. Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*. 2005; 366: 1849-1861.
47. The AIM-HIGH Investigators. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. *N Engl J Med*. 2011; 365: 2255-2267.
48. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet*. 2007; 369: 1090-1098.
49. Poli A, Marangoni F, Volpe R, et al. Nutrition Foundation of Italy. Non-pharmacological control of plasma cholesterol levels. *Nutr Metab Cardiovasc Dis*. 2008; 18: S1-S16.
50. De Nitto S, Gaddi AV, Volpe R, et al. Proteine della soia: effetti metabolici e ruolo nella prevenzione cardiovascolare. Pacini Ed, 2010.
51. Volpe R, Niittynen L, Korpela R, et al. Effects of yoghurt enriched with plant sterols on serum lipids in patients with moderate hypercholesterolemia. *Br J Nutr* 2001; 86: 233-239.
52. Stefanutti C, Mazza F, Vivencio V, et al. Combined treatment with DiflStat and diet reduce plasma lipid indicators of moderate hypercholesterolemia more effectively than diet alone: a randomized trial in parallel groups. *Lipids*. 2009; 44: 1141-1148.
53. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. *Circulation* 2009; 119: 3028-3035.
54. Colivicchi F, Guido V, Ficili S, et al. Withdrawal of statin therapy is associated with an adverse outcome after non-ST elevation acute coronary syndrome. *Eur Heart J*. 2004; 25 (suppl): 49.
55. Colivicchi F, Tubarom, Santini M. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes, *Int J Cardiol* (2010), doi:10.1016/j.ijcard.2010.07.006.
56. Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. *Stroke*. 2007; 38: 2652-2657.
57. Colivicchi F, Uguccioni M, Ragonese M, et al. Cardiovascular risk factor control among diabetic patients attending community-based diabetics care clinics in Italy. *Diab Res Clin-Prac*. 2007; 75: 176-183.
58. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. *Cochrane Database Syst Rev*. 2010; (3):CD004371.